Imatinib-Functionalized Galactose Hydrogels Loaded with Nanohydroxyapatite as a Drug Delivery System for Osteosarcoma: In Vitro Studies

Abstract

This study reports an impact of structure (XRPD, FT-IR) and surface morphology (SEM-EDS) of imatinib-functionalized galactose hydrogels, loaded and unloaded with nHAp, on osteosarcoma cell (Saos-2 and U-2OS) viability, levels of free oxygen radicals, and nitric oxide, levels of BCL-2, p53, and caspase 3 and 9, as well as glycoprotein-P activity. It was investigated how the rough surface of the crystalline hydroxyapatite-modified hydrogel affected amorphous imatinib (IM) release. The imatinib drug effect on cell cultures has been demonstrated in different forms of administrationdirectly to the culture or the hydrogels. Administration of IM and hydrogel composites could be expected to reduce the risk of multidrug resistance development by inhibiting Pgp.

68Ga‐labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity

“…However, some side effects such as fatigue, edema, nausea, vomiting, anorexia, and diarrhea were reported at high doses of imatinib (Modi et al, 2005). Therefore, to increase the efficacy and minimize the nonhematologic toxic effects of imatinib, it was encapsulated in different drug delivery systems including liposomes as one of the novel approaches in the literature (Bhattacharya, 2021; Jose et al, 2019; Karimi Ghezeli et al, 2019; Sobierajska et al, 2023).…”